Last updated on August 2018

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure


Brief description of study

INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.

Detailed Study Description

Influenza leads to significant morbidity and mortality, particularly in patients with cardiovascular disease. Influenza-related death is more common in patients with cardiovascular disease than any other chronic health condition. Influenza infection has been temporally associated with acute cardiovascular events, such as acute coronary syndrome and acute heart failure. Due to the increased risk for influenza-related complications, annual influenza immunization is recommended by the Centers for Disease Control and Prevention, (CDC) the American Heart Association, and the American College of Cardiology, and widespread influenza vaccination has been associated with reduced cardiac-related hospital admissions, acute exacerbations of heart failure, and winter mortality. Moreover, a meta-analysis has shown that annual vaccination reduces the risk for major adverse cardiovascular events (MACE) by 36%, with a more prominent effect in those with recent acute myocardial infarction (AMI).

Several lines of evidence suggest that a strategy of utilizing high-dose influenza vaccine in at risk cardiovascular patients would reduce morbidity and mortality. Immune responses to influenza vaccine, normally subject to variability by age and concomitant medical conditions, are substantially reduced in patients with heart failure evidenced by lower vaccine-induced antibody titers compared to healthy controls. In a randomized trial, antibody responses in patients with heart failure were augmented by using a higher dose of influenza vaccine. In a meta-analysis, higher dose influenza vaccination was associated with a 27% reduced risk for MACE compared to standard dose vaccine. A randomized study of high dose versus standard dose influenza vaccine in medically-stable patients over age 65 showed that participants receiving high dose vaccine had a 24% reduced risk of laboratory-confirmed influenza associated with protocol-defined influenza-like-illness, and had a low risk for adverse events. High dose influenza vaccine is FDA approved for use in medically stable adults over the age of 65, but has not been studied for patients under the age of 65 or in those with unstable, high risk medical conditions. The CDC does not preferentially recommend one influenza vaccine over another, and the optimal vaccine formulation that offers the most clinical protection in these high risk patients is unknown.

The high morbidity and health care costs among patients with high risk cardiovascular disease along with the reduced immune responses to standard dose influenza vaccines in patients with heart failure provides a compelling rationale to investigate alternative influenza vaccination strategies in this group. INVESTED is an outcomes study in patients with recent acute myocardial infarction (AMI) or heart failure (HF) to test whether a four-fold higher dose of trivalent influenza vaccine will reduce morbidity and mortality compared to standard dose quadrivalent vaccine. INVESTED will test the hypothesize that high dose vaccine will reduce the composite of all cause death or cardiopulmonary hospitalizations in this population, with the following specific aims:

Specific Aim 1. To test the hypothesis that high dose trivalent influenza vaccine will reduce the composite of death or cardiopulmonary events compared with standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients. Patients with recent AMI or HF hospitalization will be randomized to high dose versus standard dose vaccine for up to three influenza seasons. The primary endpoint will be time to first occurrence of death or cardiopulmonary hospitalization within each influenza season. Hospitalizations will be ascertained utilizing multiple approaches (phone, patient report, and electronic health records). Key secondary outcome measures will include total (first and recurrent) cardiopulmonary hospitalizations or death, time to first occurrence of cardiovascular death or cardiopulmonary hospitalization, time to occurrence of all-cause death or cardiopulmonary hospitalization across all enrolled influenza seasons, time to occurrence of all-cause death, and time to first occurrence of cardiopulmonary hospitalizations.

Specific Aim 2. To test the hypothesis that antibody titers to influenza vaccine antigens are associated with cardiopulmonary outcomes. In a subset of participants, antibody titers by hemagglutination inhibition assays to influenza vaccine antigens at baseline and at 4 weeks following randomization will be determined, corresponding to achievement of maximal antibody titer levels after vaccination. The association between geometric mean titers post-vaccination and the occurrence of death or cardiopulmonary hospitalization (primary outcome measure of Specific Aim 1) will be assessed.

Other key correlative study (immune) outcome measures will include:

Change in antibody titers at 4 weeks post-vaccination from baseline to influenza vaccine antigens Seroconversion (demonstration of 4-fold rise in antibody concentrations from baseline) and seroprotection (demonstration of antibody titer level of 1:40) to A/H1N1, A/H3N2, and B-type vaccine antigens

The results of this trial have the potential to inform health care policy regarding optimal influenza vaccination for individuals with high risk cardiovascular disease, which may in turn reduce morbidity from this annual threat to health stability in patients with cardiovascular conditions.

Clinical Study Identifier: NCT02787044

Find a site near you

Start Over

Louis A Johnson VAMC

Clarksburg, WV United States
  Connect »

St. Louis University

Saint Louis, MO United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

University of Wisconsin

Madison, WI United States
  Connect »

Charles George VA

Asheville, NC United States
  Connect »

VA Medical Center White River Junction

White River Junction, VT United States
  Connect »

Carient Heart & Vascular

Manassas, VA United States
  Connect »

University of Utah

Salt Lake City, UT United States
  Connect »

St. Catherines Hospital

St. Catherines, ON Canada
  Connect »

University of Pittsburgh

Pittsburgh, PA United States
  Connect »

Meharry Medical College

Nashville, TN United States
  Connect »

Dr. James Cha

Oshawa, ON Canada
  Connect »

VA San Diego Healthcare System

San Diego, CA United States
  Connect »

ENRM VA Hospital

Bedford, MA United States
  Connect »

Krannert Institute of Cardiology

Indianapolis, IN United States
  Connect »

St. Paul's Hospital

Vancouver, BC Canada
  Connect »

VA Boston Healthcase System

West Roxbury, MA United States
  Connect »

Washington DC VAMC

Washington, WA United States
  Connect »

PACE

Newmarket, ON Canada
  Connect »

Vanderbilt University

Nashville, TN United States
  Connect »

Boston/West Roxbury VA Hospital

West Roxbury, MA United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

TotalCardiology

Calgary, AB Canada
  Connect »

VAMC Memphis

Memphis, TN United States
  Connect »

Chicago Medical Research

Hazel Crest, IL United States
  Connect »

Ohio State University

Columbus, OH United States
  Connect »

University of Minnesota

Minneapolis, MN United States
  Connect »

VA St. Louis Health Care System

Saint Louis, MO United States
  Connect »

N FL/S GA Veterans Health System

Gainesville, FL United States
  Connect »

Abbott Northwestern Hospital

Minneapolis, MN United States
  Connect »

Temple University

Philadelphia, PA United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »

Lourdes Cardiology Services

Voorhees, NJ United States
  Connect »

NYU Langone Medical Center

New York, NY United States
  Connect »

Palmetto Research Center, LLC

Spartanburg, SC United States
  Connect »

New Mexico VA Health Care System

Albuquerque, NM United States
  Connect »

Kansas City VA Medical Center

Kansas City, MO United States
  Connect »

OneFlorida CDRN

Gainesville, FL United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

iHealthCentre

Vaughan, ON Canada
  Connect »

Aurora Research Institute, LLC

Milwaukee, WI United States
  Connect »

Oregon Health & Science

Portland, OR United States
  Connect »

STAR Clinical Trials

San Antonio, TX United States
  Connect »

UCSF Medical Center

San Francisco, CA United States
  Connect »

Pentucket Medical Associates

Haverhill, MA United States
  Connect »

Austin Heart San Marcos

San Marcos, TX United States
  Connect »

Duke

Durham, NC United States
  Connect »

Northwester Medicine Lake Forest

Lake Forest, IL United States
  Connect »

VA West Haven

West Haven, CT United States
  Connect »

Kawartha Cardiology

Peterborough, ON Canada
  Connect »

University of Hawaii

Honolulu, HI United States
  Connect »

Robley Rex VA

Louisville, KY United States
  Connect »

IUCPQ

Quebec City, QC Canada
  Connect »

Charlotte Heart Group Research Center

Port Charlotte, FL United States
  Connect »

Heart House Research Foundation

Springfield, OH United States
  Connect »

Heart Center Research, LLC

Huntsville, AL United States
  Connect »

Stony Brook University Hospital

Stony Brook, NY United States
  Connect »

New York VA

New York, NY United States
  Connect »

Gundersen Clinic

La Crosse, WI United States
  Connect »

Birmingham VAMC

Birmingham, AL United States
  Connect »

ITB Research

Miami, FL United States
  Connect »

VA Loma Linda Healthcare System

Loma Linda, CA United States
  Connect »

CAVHS

Little Rock, AR United States
  Connect »

The Heart Clinic of Hamond

Hammond, LA United States
  Connect »

WJB Dorn VAMC

Columbia, SC United States
  Connect »

Providence VA Medical Center

Providence, RI United States
  Connect »

Dr. Alan David Bell

Downsview, ON Canada
  Connect »

Albany Medical College

Albany, NY United States
  Connect »

Marshfield Clinic

Marshfield, WI United States
  Connect »

Long Beach VAMC

Long Beach, CA United States
  Connect »

Piedmont Heart Institute

Atlanta, GA United States
  Connect »

Peidmont Fayette

Fayetteville, GA United States
  Connect »

Central DuPage Hospital

Winfield, IL United States
  Connect »

St. Vincent Medical Group

Indianapolis, IN United States
  Connect »

University of Iowa

Iowa City, IA United States
  Connect »

New York Presbyterian/Queens

Flushing, NY United States
  Connect »

New York Presbyterian

New York, NY United States
  Connect »

Dixie Medical Group

Mississauga, ON Canada
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.